MariMed (OTCMKTS:MRMD) Stock Rating Lowered by Zacks Research

Key Points

• Research firm Zacks Research downgraded MariMed (OTCMKTS:MRMD) from a "strong-buy" to a "hold" rating as of Monday.
• MariMed's stock is currently trading at $0.17, with a 52-week range between $0.07 and $0.23.
• The company has a market capitalization of $65.76 million and a debt-to-equity ratio of 1.25.

MariMed (OTCMKTS:MRMD - Get Free Report) was downgraded by research analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued on Monday,Zacks.com reports.

MariMed Stock Up 1.5%

Shares of MRMD opened at $0.17 on Monday. MariMed has a 52 week low of $0.07 and a 52 week high of $0.23. The company has a debt-to-equity ratio of 1.25, a quick ratio of 0.36 and a current ratio of 1.12. The firm has a market capitalization of $65.76 million, a P/E ratio of -5.58 and a beta of 2.98. The company has a 50-day simple moving average of $0.14 and a 200-day simple moving average of $0.11.

MariMed Company Profile

MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.